In both in vitro and in vivo studies, a combination of the ER antagonist and the EGFR tyrosine kinase inhibitor has been shown to decrease cell proliferation and tumor growth more than monotherapy either with ER antagonists or EGFR TKI [34,60,67]. The gene discussed is EGFR; the disease is neoplasm.